This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacqueline, C. Articles by Potel, G. Search for Related Content PubMed PubMed Citation Articles by Jacqueline, C. Articles by Potel, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antibiotics MRSA Staphylococcal Infections Hazardous Substances DB VANCOMYCIN

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3397-3400, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01242-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model

Cédric Jacqueline,¹ Jocelyne Caillon,^1* Virginie Le Mabecque,¹ Anne-Françoise Miègeville,¹ Antoine Hamel,¹ Denis Bugnon,¹ James Yigong Ge,² and Gilles Potel¹

Université de Nantes, Nantes Atlantique Universités, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, UFR Médecine, Nantes, France,¹ Cerexa, Inc., Alameda, California²

Received 4 October 2006/ Returned for modification 28 January 2007/ Accepted 9 June 2007

Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.

---

* Corresponding author. Mailing address: UPRES EA 3826, UER de Médecine, 1 rue Gaston Veil, 44035 Nantes, Cedex 01, France. Phone and fax: (33) 240-41-2854. E-mail: jocelyne.caillon{at}univ-nantes.fr

Published ahead of print on 25 June 2007.

---

Antimicrobial Agents and Chemotherapy, September 2007, p. 3397-3400, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01242-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Vidaillac, C., Leonard, S. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model. Antimicrob. Agents Chemother. 53: 4712-4717 [Abstract] [Full Text]  
• Llarrull, L. I., Fisher, J. F., Mobashery, S. (2009). Molecular Basis and Phenotype of Methicillin Resistance in Staphylococcus aureus and Insights into New {beta}-Lactams That Meet the Challenge. Antimicrob. Agents Chemother. 53: 4051-4063 [Full Text]  
• Brown, S. D., Traczewski, M. M. (2009). In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing. Antimicrob. Agents Chemother. 53: 1271-1274 [Abstract] [Full Text]  
• Sader, H. S., Fritsche, T. R., Jones, R. N. (2008). Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 1153-1155 [Abstract] [Full Text]